BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model Post published:February 15, 2022 Post category:Press Release
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001 Post published:January 20, 2022 Post category:Press Release
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001 Post published:January 18, 2022 Post category:Press Release
BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders Post published:September 27, 2021 Post category:Press Release
BetterLife Announces Closing of a Non-Brokered Private Placement Post published:May 14, 2021 Post category:Press Release
BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs Post published:April 29, 2021 Post category:Press Release
Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor Post published:April 8, 2021 Post category:Press Release
BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003 Post published:March 11, 2021 Post category:Press Release
BetterLife Enters Research Agreement with Carleton University for TD-0148A Depression Studies Post published:March 8, 2021 Post category:Press Release
BetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing Post published:March 3, 2021 Post category:Press Release